FTC Wants More Info On Genzyme/Ilex Merger; Firms See No Delay In Deal
The inquiry is spurred by independent studies on Ilex’ leukemia agent Campath for transplant treatment, which could overlap with Genzyme’s Thymoglobulin.
The inquiry is spurred by independent studies on Ilex’ leukemia agent Campath for transplant treatment, which could overlap with Genzyme’s Thymoglobulin.